MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Country |
 USA |
IPO year |
1992 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
1.25 B |
Market Cap[1] |
$ 155 B |
EBITDA (LTM) |
$ 9.3 B |
P/E (LTM) |
20.51 |
P/S (LTM) |
5.36 |
EPS (LTM) |
6.09 |
Gilead Sciences is an American biopharmaceutical company that specializes in the development and production of innovative drugs for the treatment of various diseases.
The company was founded in 1987 and is currently one of the leaders in the field of biotechnology. It conducts research and development in areas such as infectious diseases, oncology, hepatitis, HIV infection, and other areas of medicine.
The company's most well-known and successful product is Sovaldi, which is the first drug to effectively treat chronic hepatitis C. The company also produces drugs for the treatment of blood cancer and HIV infection.
Gilead Sciences actively collaborates with scientific and medical institutions around the world and invests in the development of new methods for treating diseases. The company also provides training programs for medical professionals and patients.
Gilead Sciences continues to grow and expand its activities to help people around the world fight various diseases.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Adagene
ADAG
|
$ 1.9 | -3.11 % | $ 107 M | Nasdaq Global Market |  China |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.88 | -0.73 % | $ 1.25 B | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.31 | -4.06 % | $ 7.96 B | Nasdaq Capital Market |  Australia |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.7 | 1.5 % | $ 17 M | Nasdaq Capital Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.9 | 0.52 % | $ 908 M | Nasdaq Capital Market |  Israel |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
BioNTech SE
BNTX
|
$ 106.07 | -2.69 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.96 | -1.0 % | $ 8.62 B | NYSE American | Israel |
 |
CASI Pharmaceuticals
CASI
|
$ 0.95 | -0.72 % | $ 129 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 215.17 | 4.54 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Bio-Path Holdings
BPTH
|
- | - | $ 100 K | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 25.17 | -1.89 % | $ 1.62 M | Nasdaq Global Select Market | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 64.51 | 1.04 % | $ 8.63 B | Nasdaq Global Select Market,SPB | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 23.24 | 2.38 % | $ 2.75 B | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 9.65 | -0.72 % | $ 1.56 B | NYSE | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.0 | 3.63 % | $ 922 M | Nasdaq Capital Market | USA |
 |
Biogen
BIIB
|
$ 164.49 | 0.04 % | $ 23.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
BioVie
BIVI
|
$ 1.24 | 2.49 % | $ 1.83 M | Nasdaq Capital Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.